供者或受者存在遗传性染色体整合型HHV-6的造血细胞移植结局
该研究对4319对接受异基因造血细胞移植的供受者配对(共8638人)的移植前外周血单个核细胞样本进行遗传性染色体整合型HHV-6(iciHHV-6)筛查,发现60例受者(1.4%)和40例供者(0.9%)携带iciHHV-6,共87例移植(2%)涉及受者、供者或两者携带iciHHV-6。受者或供者携带iciHHV-6时急性GVHD 2-4级更常见(aHR 1.7-1.9,P=.004-.001),受者携带iciHHV-6时巨细胞病毒血症(任何水平和高水平)更常见(aHR 1.7-3.1,P=.001-.040),而慢性GVHD、造血细胞植入、总体死亡率或非复发死亡率风险无显著影响。
要点
- 受者或供者携带iciHHV-6时急性GVHD 2-4级更常见(aHR 1.7-1.9,P=.004-.001)。
- 受者携带iciHHV-6时巨细胞病毒血症(任何及高水平)更常见(aHR 1.7-3.1,P=.001-.040)。
- iciHHV-6状态对慢性GVHD、植入、总体死亡率或非复发死亡率无显著影响。
核心结论
- 受者或供者携带iciHHV-6与急性GVHD 2-4级及受者巨细胞病毒血症风险升高相关,但未显著影响慢性GVHD、造血细胞植入、总体死亡率或非复发死亡率。
- 筛查iciHHV-6可能有助于指导供者选择和移植后风险分层及治疗。
- 需进一步研究以重复这些发现并确定潜在机制。
研究设计与样本
- 研究纳入4319对接受异基因造血细胞移植且有移植前外周血单个核细胞样本存档的供受者配对(共8638人)。
- 对样本进行iciHHV-6筛查,比较携带与不携带iciHHV-6的受者和供者特征。
- 采用Kaplan-Meier概率估计和Cox比例风险模型分析基于受者和供者iciHHV-6状态的移植后结局。
主要发现
- 60例受者(1.4%)和40例供者(0.9%)携带iciHHV-6,13例移植中受者和供者均携带iciHHV-6,共87例移植(2%)涉及受者、供者或两者携带iciHHV-6。
- 受者或供者携带iciHHV-6时急性GVHD 2-4级更常见(校正风险比1.7-1.9;P=.004-.001)。
- 受者携带iciHHV-6时巨细胞病毒血症(任何及高水平)更常见(校正风险比1.7-3.1;P=.001-.040)。
- iciHHV-6状态未显著影响慢性GVHD、造血细胞植入、总体死亡率或非复发死亡率风险。
临床怎么用
- 筛查iciHHV-6可能有助于指导供者选择和移植后风险分层及治疗。
局限性
- 需进一步研究以重复这些发现并确定潜在机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Human herpesvirus 6 (HHV-6) species have a unique ability to integrate into chromosomal telomeres. Mendelian inheritance via gametocyte integration results in HHV-6 in every nucleated cell. The epidemiology and clinical effect of inherited chromosomally integrated HHV-6 (iciHHV-6) in hematopoietic cell transplant (HCT) recipients is unclear. We identified 4319 HCT donor-recipient pairs (8638 subjects) who received an allogeneic HCT and had archived pre-HCT peripheral blood mononuclear cell samples. We screened these samples for iciHHV-6 and compared characteristics of HCT recipients and donors with iciHHV-6 with those of recipients and donors without iciHHV-6, respectively. We calculated Kaplan-Meier probability estimates and Cox proportional hazards models for post-HCT outcomes based on recipient and donor iciHHV-6 status. We identified 60 HCT recipients (1.4%) and 40 donors (0.9%) with iciHHV-6; both recipient and donor harbored iciHHV-6 in 13 HCTs. Thus, there were 87 HCTs (2%) in which the recipient, donor, or both harbored iciHHV-6. Acute graft-versus-host disease (GVHD) grades 2-4 was more frequent when recipients or donors had iciHHV-6 (adjusted hazard ratios, 1.7-1.9; P = .004-.001). Cytomegalovirus viremia (any and high-level) was more frequent among recipients with iciHHV-6 (adjusted HRs, 1.7-3.1; P = .001-.040). Inherited ciHHV-6 status did not significantly affect risk for chronic GVHD, hematopoietic cell engraftment, overall mortality, or nonrelapse mortality. Screening for iciHHV-6 could guide donor selection and post-HCT risk stratification and treatment. Further study is needed to replicate these findings and identify potential mechanisms.
引用
- Hill JA, Magaret AS, Hall-Sedlak R, et al. Outcomes of hematopoietic cell transplantation using donors or recipients with inherited chromosomally integrated HHV-6. Blood. 2017. PMID: 28596425. doi:10.1182/blood-2017-03-775759
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。